Abstract
Current pharmacological treatments for eating disorders and obesity are of limited value and thus the identification of novel targets is highly needed to enhance the development of more effective drugs. Among the bottlenecks limiting the introduction of new medicines is the reported heterogeneity of these diseases, which makes it difficult to find drugs with broad activity and the lack of animal models with translational validity, especially in the case of anorexia nervosa. Some kinds of obesity and eating disorders can be classified within the pathologies affecting the brain reward system together with drug addiction and others, and therefore specific treatments in these cases can be directed to restore normal function in brain reward pathways. Target identification in this field can greatly benefit from the combined application of genomic/proteomic techniques and robust animal models of reward deficits.
Keywords: Obesity, eating disorders, reward deficit, addiction
Current Pharmaceutical Design
Title: Identification of New Drug Targets and Biomarkers Related to Obesity and Eating Disorders: an Approach Based on Reward Deficit and Addiction
Volume: 17 Issue: 5
Author(s): Luis F Alguacil, Elisabet Salas and Carmen Gonzalez-Martin
Affiliation:
Keywords: Obesity, eating disorders, reward deficit, addiction
Abstract: Current pharmacological treatments for eating disorders and obesity are of limited value and thus the identification of novel targets is highly needed to enhance the development of more effective drugs. Among the bottlenecks limiting the introduction of new medicines is the reported heterogeneity of these diseases, which makes it difficult to find drugs with broad activity and the lack of animal models with translational validity, especially in the case of anorexia nervosa. Some kinds of obesity and eating disorders can be classified within the pathologies affecting the brain reward system together with drug addiction and others, and therefore specific treatments in these cases can be directed to restore normal function in brain reward pathways. Target identification in this field can greatly benefit from the combined application of genomic/proteomic techniques and robust animal models of reward deficits.
Export Options
About this article
Cite this article as:
F Alguacil Luis, Salas Elisabet and Gonzalez-Martin Carmen, Identification of New Drug Targets and Biomarkers Related to Obesity and Eating Disorders: an Approach Based on Reward Deficit and Addiction, Current Pharmaceutical Design 2011; 17 (5) . https://dx.doi.org/10.2174/138161211795164158
DOI https://dx.doi.org/10.2174/138161211795164158 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Protein Phosphatase 2A in Alzheimers Disease
Current Alzheimer Research Association of Smoking and Alcohol Drinking with Dementia Risk Among Elderly Men in China
Current Alzheimer Research Ca<sub>v</sub>1.3 Channels as Key Regulators of Neuron-Like Firings and Catecholamine Release in Chromaffin Cells
Current Molecular Pharmacology Stress, Depression and Hippocampal Apoptosis
CNS & Neurological Disorders - Drug Targets Pharmacogenetics of Alcohol and Alcohol Dependence Treatment
Current Pharmaceutical Design Dysregulated Chemokine Signaling in Cystic Fibrosis Lung Disease: A Potential Therapeutic Target
Current Drug Targets Restriction Factors in HIV-1 Disease Progression
Current HIV Research Recent Patents and Trends in Orally Disintegrating Tablets
Recent Patents on Drug Delivery & Formulation Editorial (Current and Emerging Pharmacological Therapies of Ischaemic Stroke)
CNS & Neurological Disorders - Drug Targets Random Walks on Biomedical Networks
Current Proteomics Structural Insights for Drugs Developed for Phospholipase D Enzymes
Current Drug Discovery Technologies The role of interleukin 35 in atherosclerosis
Current Pharmaceutical Design Effects of Gene and Plasma Tau on Cognitive Impairment in Rural Chinese Population
Current Alzheimer Research Inhibitors and Breakers of Advanced Glycation Endproducts (AGEs): A Review
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Eriocalyxin B-Induced Apoptosis in Pancreatic Adenocarcinoma Cells Through Thiol-Containing Antioxidant Systems and Downstream Signalling Pathways
Current Molecular Medicine Prevalence of the Use of Opioids for Treatment of Pain in Persons with a Cognitive Impairment Compared with Cognitively Intact Persons: A Systematic Review
Current Alzheimer Research Tetracyclines and Pulmonary Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets 6-Benzothiazolyl Ureas, Thioureas and Guanidines are Potent Inhibitors of ABAD/17β-HSD10 and Potential Drugs for Alzheimer"s Disease Treatment: Design, Synthesis and in vitro Evaluation
Medicinal Chemistry Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy
Current Drug Targets Drug Resistance and Methylation in Myelodysplastic Syndrome
Current Pharmaceutical Biotechnology